We investigated idiotypic markers of monoclonal antibodies derived from patients with polyclonal B-cell activation. Four monoclonal antibodies with different ligand binding specificities derived from a patient with lepromatous leprosy and three monoclonal anti-DNA antibodies from two patients with SLE were studied. Three new public idiotopes, which were common to monoclonal antibodies from all three patients, were defined by five polyclonal rabbit antiidiotypes, two monoclonal mouse antiidiotopes, and a monoclonal mouse antibody against a synthetic peptide that contains residues of the heavy chain CDR-1 of a monoclonal lupus anti-DNA antibody. The antibody against the synthetic idiotype was found to react with native immunoglobulins in solution. One idiotope was found to be consistently immunogenic in all animals tested. Since the three patients are of different ethnic origins, these shared idiotypes are probably encoded by germline V genes. These genes may be recurrently expressed in states of polyclonal B-cell activation, regardless of etiology. The results suggest that some autoantibodies arise by expansion of a pool of precursors in the normal antibody repertoire.
Introduction
The immunoglobulin variable region contains antigenic determinants, termed idiotypes, which can be recognized by serological techniques. In a typical case, an idiotype of a monoclonal human antibody is defined by an antiidiotypic antiserum raised in a rabbit. If the defining serological reagent is itself a monoclonal antibody, then the variable region antigen is termed an idiotope. The structure that determines the serological specificity of an idiotype may reside in either the heavy or light chain of the variable region ( 1-3), or it may consist ofan antigenic surface made up of both chains (4) (5) (6) . An idiotype, therefore, is a serologically defined product of immunoglobulin V genes (7) . Idiotypes are of considerable interest because they are recognition elements in regulatory networks of B cells and T cells (8) ; and, when used as serological markers, they can trace the origins of idiotypically related antibodies. This paper deals with idiotypic markers of monoclonal antibodies derived from patients with leprosy or systemic lupus erythematosus (SLE).' In both disorders there is polyclonal B cell activation, a common event in many infectious and autoimmune diseases; and in both conditions there are autoantibodies against diverse, ubiquitous autoantigens like DNA (9, 10) . The particular question we addressed was whether antibodies produced in leprosy and SLE share common idiotypic markers, despite the different causes and predisposing factors ofthese two diseases (1 1, 12) . We found that some leprosy-and lupus-derived monoclonal antibodies bear closely related, probably highly conserved, idiotypes. Our results support the hypothesis that certain idiotypic markers are recurrently expressed in polyclonal B cell activation, regardless of its cause.
Methods
Human monoclonal antibodies. As previously described (13) , peripheral lymphocytes from patients with SLE or leprosy were fused with cells of the GM4672 cell line. Before fusion the lymphocytes were stimulated with pokeweed mitogen (Gibco Laboratories, Grand Island, NY), and also, in the case ofthose from the patient with leprosy, with staphylococcal protein A (The Enzyme Center, Inc., Boston, MA). Immunoglobulinproducing clones were selected, subcloned, and expanded, and the immunoglobulins were purified from culture supernatants on goat antihuman IgM (Cappel Laboratories, Cochranville, PA) linked to Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, NJ). Seven monoclonal antibodies were used in the present study. All were of the IgM isotype. Four ofthem (8E7, 4D5, 4G7, and TH9) were derived from the peripheral lymphocytes of a male from Thailand with borderline lepromatous leprosy (Duggan, D., et al., manuscript in preparation); one (16/6) was derived from the peripheral lymphocytes of an American male of Irish/ Scottish descent with SLE (13) ; the remaining two (I1/13 and 21/28) were derived from the peripheral and splenic lymphocytes, respectively, ofan Iranian woman with SLE (13) . The ligands identified for these antibodies are summarized in Table I .
Polyclonal rabbit antisera. Rabbit polyclonal anti-idiotypic sera were raised against the four leprosy monoclonals 8E7, 4D5, 4G7 and TH9 and the lupus monoclonal 16/6. (The antiserum against 16/6 was distinct from that generated in a previous study [16] Mouse monoclonal antiidiotypes. The generation of mouse monoclonal anti-16/6 has been previously described (17) . In order to generate a mouse monoclonal antibody against the human leprosy-derived monoclonal 8E7, a 12-wk old BALB/c mouse (Jackson Laboratories) was immunized with purified 8E7. Complete and incomplete Freund's adjuvant were used for the first and second injections; these were given intraperitoneally. Four subsequent injections of 8E7 in PBS only were given intravenously and intraperitoneally, the last three being administered 6, 3, and 1 d before fusion. Splenocytes from the mouse were fused with cells from the NSl myeloma cell line using 44% polyethylene glycol (J. J. Baker Chemical Co., Phillipsburg, NJ) according to a standard protocol (18) . The fused cells were plated, selected in medium containing hypoxanthine, aminopterin, and thymidine (HAT), and subcloned as previously described (18) . Culture supernatants from wells showing hybridoma growth were tested for ELISA for immunoglobulin production and anti-idiotype activity against 8E7. The cells from selected wells were subcloned at 0.5 cells per well and retested. After five such subcloning procedures a stable antiidiotype-producing line was isolated. These cells were then grown in bulk, and the supernatant harvested and stored in 0.02% azide and 2 mM phenylmethylsulphonylfluoride (PMSF; Sigma Chemical Co.) at 4°C.
Synthetic peptides. The sequences of the first 40 amino-acids of the amino terminal portion of the heavy chains of 16/6 and 1/13 have been determined in a previous study (19) . A 12 amino acid peptide (peptide "D") was synthesized which contains residues ofthe first complementarity determining region (CDR-I) of the 16/6 heavy chain, together with seven flanking amino acids. The sequence of this peptide begins at amino acid residue 27, and is as follows: Phe-Ser-Phe-Ser-Pro-Ser-Ala-Met-Ser-TrpVal-Arg. An irrelevant peptide ("F', Leu-Ile-Tyr-Gly-Ala-Thr-Ser-LeuGln-Ser-Gly-Val-Pro) was used as a control. The synthesis of these peptides was performed by Dr. S. Wood, University Hospital, Boston University Medical Center. The peptides were linked to keyhole limpet hemocyanin (KLH, Sigma Chemical Co.) by an adaptation ofa previously described method (20) . A mixture ofequal weight (2-5 mg) oflyophilized KLH and the lyophilized peptide was prepared in a final volume of 0.7 ml of0.25 M K2P04, pH 7.2. 4 y1 of 25% glutaraldehyde (Fisher Scientific Co.) was added to the solution, the mixture was vortexed and then allowed to stand at room temperature (RT) for 30 min. It was then dialyzed against three changes of PBS/0.02% azide, and stored at -20°C until use. Linking of peptide D to bovine serum albumin (BSA) (Fisher Scientific Co.) was carried out using the same method. As a control, BSA was treated in the same way in the absence of peptide.
Generation ofmonoclonal antibody against peptide D. A 1 2-wk-old BALB/c mouse (Jackson Laboratories) was injected intraperitoneally with peptide D-KLH conjugate (500 ltg of KLH) in complete Freund's adjuvant, followed by a further injection (250 Mg of KLH) intravenously/ intraperitoneally in PBS 2 wk later. 5 d after the second injection splenocytes from the mouse were fused with NS I cells. The methods for cell fusion, plating, HAT selection and subcloning were the same as those described above. Clones were selected by ELISA for the production of immunoglobulin which bound specifically to peptide D linked to KLH (D-KLH) or (D-BSA) and not to peptide F linked to BSA (F-BSA), or to BSA alone, glutaraldehyde-treated or untreated. After three subcloning procedures a stable antipeptide cell line was isolated. This was grown in bulk. The harvesting and storage ofculture supernatant were performed as above.
Determination ofimmunoglobulin concentration. A standard ELISA method was used. Microtiter plates (Immulon 1, Dynatech Laboratories, Alexandria, VA) were coated with the relevant antiserum (e.g., goat antihuman IgM) at 1 ug/ml. The plates were blocked with 3% BSA and the test samples applied in serial dilutions (2 h at RT). Myeloma immunoglobulins (IgM or IgG; Cappel Laboratories) were used to generate control curves. Alkaline phosphatase (ALP)linked second step antibodies (e.g., [ALP]-linked goat anti-human IgM [Sigma Chemical Co.]) were then added, followed by the developing substrate.
Detection ofantiidiotypes. Two methods, direct binding and liquidphase competition, were used for detection and quantitation of crossreacting idiotypes. In the direct method, microtiter plates were coated with human monoclonal antibody or as a negative control, with NHIgM at 0.75 g/ml. The plates were blocked with 3% BSA and the antiidiotype reagent was then added in serial dilutions, e.g., rabbit antiserum, mouse hybridoma culture fluid or purified mouse monoclonal antibody (2 h at RT); negative controls included normal rabbit serum (extensively absorbed on normal human IgG and IgM) and TEPC 183 or UPC 10 (Litton Bionetics, Kensington, MD) in NS1 culture supernatant or in PBS/0.1% Tween (Fisher Scientific Co.). The appropriate second-step ALP-linked antibody was then added (e.g., goat anti-rabbit IgG, goat anti-mouse IgM or IgG), followed by developing substrate. Curves generated by such direct binding assays were used to determine the optimum dilution of antiidiotype for use in competition experiments. For rabbit anti-16/6, -8E7, -4G7, -4D5, and -TH9 these were 1:500, 1:1,000, 1:2,000, 1:1,000, and 1:20,000, respectively; for culture fluids of mouse anti-16/6, -8E7, and -D they were 1:20, 1:2, and 1:4, respectively. For purified mouse anti-16/6 the optimum concentration was 0.75 ,ug/ml.
For competition assays the human monoclonal antibody bearing the idiotype under examination was coated on the solid phase at a concentration determined by direct binding experiments (usually 0.75 Ag/ml);
NHIgM was used as a negative control. The plates were blocked with 3% BSA for 1 h at RT. A mixture of rabbit or mouse antiidiotype and competitor was then added. The dilution or concentration of antiidiotype was previously determined by direct binding assays. Competitors consisted of purified human, mouse or rabbit immunoglobulin. The antiidiotypes and the competitors were incubated together in their final dilutions or concentrations for I h at 370C followed by 1 h at 4VC before being put on the plate (2 h at RT). The appropriate ALP-linked second step antibody (directed against the antiidiotype, i.e., goat anti-rabbit IgG, or goat antimouse IgM or IgG) was then added (overnight at RT), followed by developing substrate.
Immunoabsorption ofrabbit antisera. In order to examine different subpopulations of rabbit antiidiotype antibodies, we passed individual rabbit antisera over Sepharose-4B linked to the human monoclonal antibody 16/6. The column was eluted with 0.1 M glycine/HCl pH 2.5, and the eluate dialyzed against PBS/0.02% azide. The eluate and the flow-through from the column were used in direct binding and competition assays as described above.
Results
Nomenclature. The following notations will be used for the reagents and assay systems described in this paper. The four monoclonal antibodies derived from the leprosy patient are designated 8E7, 4D5, 4G7, and TH9; the three monoclonal antibodies from the two lupus patients are 16/6 (from one patient) and 1/13 and 21/28 (from the other patient). The rabbit antiidiotypes against these monoclonal antibodies are: RId8E7, RId4D5, RId4G7, RIdTH9, and RId 16/6. The monoclonal mouse antiidiotopes are designated MId8E7 and MIdl6/6; the monoclonal antibody against peptide D is termed MD. For designating competition assays, the antibody in the liquid phase is noted first, followed by the antibody on the solid phase; e.g., RId8E7-8E7.
Idiotypes ofmonoclonal leprosy antibodies. When examined in homologous idiotype competition assays, i.e., with the immunizing monoclonal antibody on the solid phase and the corresponding rabbit antiidiotype in the liquid phase, the four leprosy antibodies exhibited little or no idiotypic cross-reactivity. In the assay RId8E7-8E7, shown in Table II , the concentration in nanograms per milliliter of 8E7 that produced 50% inhibition was 120, compared to 1,200 and 8,000 of 4G7 and 4D5; 10,000 ng/ml of TH9 did not inhibit this reaction. In the RId4D5-4D5 assay, illustrated in Fig. 1 b, 50% inhibition was produced by 26 ng/ml 4D5 and 2,000 ng/ml TH9; 10,000 ng/ml of 8E7 or 4G7 caused < 20% inhibition. Similar specificity was found for the immunizing monoclonal antibody in the RIdTH9-TH9 (Fig. 1  a) , and RId4G7-4G7 assays (Table II) . We can conclude, therefore, that each ofthe polyclonal rabbit antisera contained a population of antibodies that was relatively specific for a unique idiotypic determinant on the corresponding immunizing monoclonal antibody.
Monoclonal leprosy and lupus antibodies share idiotypes. By contrast with the preceding, a substantial degree of cross-reac- Fig. 2 , is that the inhibition curves are generally similar, indicating that the most cross-reactive monoclonal antibodies bear closely related idiotypic determinants. An idiotypic relationship between the leprosy and lupus monoclonal antibodies was also seen in an assay with 1/ 13 on the solid phase and RIdl6/6 in the liquid phase (Table II) . In this case the monoclonal antibody on the plate is structurally related to the monoclonal antibody against which the rabbit antiserum was raised (19) . Notably, the leprosy antibody 4D5 showed strong cross-reactivity in this assay; the order ofinhibition was: 1/13 (120 ng/ml) = 16/6 (120 ng/ml) > 21/28 (200 ng/ml) > 4D5 (240 ng/ml) > 4G7 (800 ng/ml) > 8E7 (1,400 ng/ml) > TH9 (3,200 ng/ml). Fig. 3 shows the inhibition curves for this assay.
The relative activities of the rabbit anti-8E7 reagent against both 8E7 and 1/13 were compared by examining the binding of serial dilutions of RId8E7 to constant concentrations of 8E7 and 1/13 on the solid phase: RId8E7 bound to 8E7 at sevenfold higher dilutions than were required for similar binding to 1/13 in this assay, while normal rabbit serum did not bind to 8E7 or 1/13 at any dilution (data not shown). In view of the similar inhibition curves in the RId8E7-1/13 competition assay (Fig.  2) [COMPETITOR] (pg/ml) tivity of the antiserum (Fig. 4) . The eluate and flow-through fractions were tested in liquid phase competition assays with 1/13 or 8E7 on the solid phase (Table III) . The results for the eluate were almost identical to those for the whole RId8E7 serum (Fig. 5) . By contrast, the only monoclonal antibody which produced any inhibition ofthe binding ofthe RId8E7 flow-through fraction to 8E7 was 8E7 itself (Fig. 6 ). This confirms that RId8E7 contains at least two populations ofantiidiotypes: one that detects a cross-reactive idiotype shared by leprosy and lupus antibodies and another more specific to 8E7, the immunizing leprosy monoclonal antibody. Similar results were obtained with eluate and flow-through fractions of RId4D5 and RId4G7 when these sera were absorbed on a 16/6-Sepharose column (Table III) . RIdTH9 was not absorbed in this way, since it showed only weak binding to 16/6 in direct binding assays.
Cross-reactive idiotopes on monoclonal leprosy and lupus antibodies. Monoclonal mouse antiidiotopes against 16/6 (MIdl6/6) and 8E7 (MId8E7) were used to probe further the relationships between leprosy and lupus antibodies. In direct binding assays, MId 16/6 bound strongly to all of the lupus-and leprosy-derived monoclonals, with the exception of TH9, and MId8E7 bound strongly to all of the antibodies except 4G7 and TH9 (data not shown). These results were confirmed by crossidiotope competition assays, shown in Fig. 7 ever, if it occurs repetitively in immunoglobulins from unrelated patients it could provide a marker of sets ofrecurrently expressed germline V genes.
To test these ideas, we selected a panel of monoclonal antibodies from patients with leprosy and SLE, diseases characterized by marked polyclonal B-cell activation (9, 10). The seven monoclonal antibodies were derived from three patients of different racial origin and they have different ligand binding properties (Table I) . Five of them are autoantibodies against DNA or mitochondria; one binds to a monoclonal antibody bearing an internal image of the acetylcholine receptor (15) , and may therefore also be an autoantibody; the binding specificity of the seventh is unknown. Of the six autoantibodies, 4G7, derived from a patient with lepromatous leprosy is of considerable in- terest. It binds to both Mycobacterium leprae and single-stranded DNA, which might indicate that the stimulus for the production of anti-DNA antibodies in leprosy is the infecting organism (Duggan, D., et al., manuscript in preparation). Four of the monoclonal antibodies bind to DNA, but the fine specificities differ in each case (14) . Both private and public idiotypes were found in the seven monoclonal antibodies. The cross-idiotype inhibition assay system that we used to identify the public idiotypes was first described with monoclonal human antibodies by Kunkel et al. (23) , and by Kindt et al. (24) with monoclonal rabbit antibodies. They emphasized the sensitivity of the method for detecting idiotypes shared by different antibodies. Our results with two antiidiotypes, RId 16/6 (prepared by immunizing a rabbit with a monoclonal lupus antibody) and RId8E7 (prepared from a monoclonal leprosy antibody), showed strong idiotypic cross reactions with a small subpopulation of antiidiotypes present in the polyclonal reagents. Further evidence for the presence of idiotypically related structures on these antibodies was obtained with monoclonal mouse antiidiotopes. The results were especially clear with a monoclonal antibody (MId8E7) against an idiotope on the leprosy antibody 8E7 (IdLLb); MId8E7 actually bound more avidly to 1/13 and 21/28 (two independently derived lupus antibodies) than to 8E7 itself.
Our results illustrate that idiotypic markers are a complex group of antigenic determinants. This is to be expected in view of the structure of the immunoglobulin variable region. Idiotypes can be serological markers of either the heavy or light chains of antibodies, or of an antigenic surface made up of portions of both chains (1) (2) (3) (4) (5) (6) . Hence, two antibodies with the same heavy chain but unrelated light chains, may, by different folding of the pairs of chains express different antigenic determinants (5) . Moreover, the identical heavy chain amino acid sequence may, in the context of different light chains, be more or less exposed to the surface of the molecule, and thus to an antiidiotype. These considerations can explain our results with MD, a monoclonal antibody against a synthetic peptide derived from the first hypervariable region, and its flanking amino acids, of the heavy chain of 16/6. The lupus antibodies 1/13 and 16/6 have nearly identical sequences in that region (19) , and their binding to MD was the same. Antibody 21/28, also from a lupus patient, but with a different CDR-1 (Dersimonian, H; unpublished data), did not bind to MD. Judging by the competitive inhibition assay shown in Fig. 8 (MD-1/ 3 ), MD was 10-fold more avid for 4D5, a leprosy antibody, than for 1/13. It would appear, therefore, that peptide "D" is more exposed on the surface of 4D5 than on 1/13, or, alternatively, that a distortion brought about by adhering 1/13 to the solid phase most closely resembles the conformation of peptide "D" in 4D5. The actual sequence recognized by MD is presently unknown. We suppose that the antigenic determinant of the peptide resides in its carboxy-terminal region, which would constitute its exposed terminus after conjugation of its NH2-terminal phenylalanines to KLH with glutaraldehyde.
The similarities between the behavior in cross-idiotype sys- (15) . Therefore, the idiotypic network to which TH9 belongs may be distinct from the network(s) that gave rise to the other antibodies in this study.
It can be argued that in vitro polyclonal B cell activation, or 
